Therefore, we designed the PERIXa study (Perioperative Factor Xa Inhibitor Discontinuation in Patients With Atrial Fibrillation Undergoing Minimal to Low Bleed Risk Procedures) to explore the association of short-term perioperative discontinuation of factor Xa inhibitors with rates of major bleeding and thromboembolism among patients with AF undergoing procedures with minimal to low bleeding risk. The gene discussed is F10; the disease is atrial fibrillation.